Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR.
apolipoprotein B
berberine
low-density lipoprotein receptor
microsomal triglyceride transfer protein
nonalcoholic fatty liver disease
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
16
04
2020
accepted:
15
02
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
ppublish
Résumé
The global incidence of nonalcoholic fatty liver disease (NAFLD) is increasing. The present study explored the effect and mechanism of berberine (BBR) on NAFLD in rats. Thirty-five Sprague-Dawley rats were randomly divided into the control and NAFLD groups, which were fed a normal diet or high-fat diet, respectively, for 8 weeks. Hematoxylin and eosin staining was performed on liver tissues and establishment of the NAFLD model was confirmed by microscopy. NAFLD rats were subsequently randomly subdivided and treated with saline or BBR for 8 weeks. The liver wet weight of rats in each group was measured, the liver tissue structure was observed by microscopy, and alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), fasting blood glucose (FBG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels were detected using a semi-automatic biochemical detector. Reverse transcription-quantitative PCR and western blotting were performed to determine the mRNA and protein expression levels of microsomal triglyceride transfer protein (MTTP), apolipoprotein B and low-density lipoprotein receptor (LDLR). Compared with the control group, the liver wet weight of the NAFLD rats was higher; the liver showed obvious fatty degeneration and liver TG levels increased significantly, as did serum levels of ALT, AST, TC, TG, FBG, HDL and LDL, while expression of MTTP and LDLR significantly decreased. Compared with the saline-treated NAFLD rats, the BBR-treated rats had reduced liver wet weight, improved liver steatosis and a significant decrease in liver TG levels, while ALT, AST, TC, TG, and LDL serum levels significantly decreased and MTTP levels were significantly upregulated. In conclusion, BBR treatment ameliorated the fatty liver induced by a high-fat diet in rats. Furthermore, BBR reversed the abnormal expression of MTTP and LDLR in rats with high-fat diet induced-NAFLD. The present findings suggest that fatty liver could be improved by BBR administration, via reversing the abnormal expression of MTTP and LDLR and inhibiting lipid synthesis.
Identifiants
pubmed: 34504563
doi: 10.3892/etm.2021.10543
pii: ETM-0-0-10543
pmc: PMC8383777
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1109Informations de copyright
Copyright: © Chen et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E794-800
pubmed: 15956049
Diabetologia. 2011 Mar;54(3):641-7
pubmed: 21153530
J Biol Chem. 2002 May 17;277(20):17377-80
pubmed: 12006608
J Biol Chem. 2004 Nov 12;279(46):47898-905
pubmed: 15371448
J Gastroenterol. 2003;38(10):954-61
pubmed: 14614602
Adv Exp Med Biol. 2016;928:27-45
pubmed: 27671811
J Biol Chem. 1998 Sep 18;273(38):24649-53
pubmed: 9733761
J Lipid Res. 2002 Mar;43(3):428-37
pubmed: 11893779
BMC Immunol. 2020 May 19;21(1):28
pubmed: 32429849
Biochem J. 1990 May 15;268(1):1-13
pubmed: 2188646
Front Pharmacol. 2020 Mar 03;11:185
pubmed: 32194416
Liver Int. 2017 Jan;37 Suppl 1:85-89
pubmed: 28052629
Trends Cardiovasc Med. 2000 Nov;10(8):338-45
pubmed: 11369260
Hepatology. 2010 Feb;51(2):679-89
pubmed: 20041406
Phytother Res. 2018 Dec;32(12):2560-2567
pubmed: 30306659
J Biol Chem. 1999 Sep 24;274(39):27793-800
pubmed: 10488124
Fundam Clin Pharmacol. 2020 Apr;34(2):238-248
pubmed: 31520444
Nat Med. 2004 Dec;10(12):1344-51
pubmed: 15531889
Lipids Health Dis. 2016 Feb 01;15:20
pubmed: 26832365
Biochem Soc Trans. 2004 Feb;32(Pt 1):59-64
pubmed: 14748713
Free Radic Biol Med. 2019 Sep;141:192-204
pubmed: 31226399
Gastroenterology. 1998 Apr;114(4):842-5
pubmed: 9547102
J Lipid Res. 2006 Jun;47(6):1281-8
pubmed: 16508037
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32440681
Curr Pharm Des. 2020;26(39):5054-5066
pubmed: 32445451
Chin J Integr Med. 2011 Mar;17(3):205-11
pubmed: 21359922
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):191-8
pubmed: 16706832
CMAJ. 2005 Mar 29;172(7):899-905
pubmed: 15795412
J Cell Biochem. 2018 Jul;119(7):5373-5381
pubmed: 29345340
Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E812-9
pubmed: 19176354
Front Pharmacol. 2020 Mar 24;11:351
pubmed: 32265720
Pharmacol Res. 2020 May;155:104684
pubmed: 32045667
Biochem Cell Biol. 2010 Apr;88(2):251-67
pubmed: 20453928
Gastroenterology. 2005 Jul;129(1):113-21
pubmed: 16012941
Science. 2011 Jun 24;332(6037):1519-23
pubmed: 21700865
J Gastroenterol Hepatol. 2010 Feb;25(2):352-6
pubmed: 19817963
Acta Pharmacol Sin. 2017 Feb;38(2):157-167
pubmed: 27917872
Eur J Pharmacol. 2018 Apr 15;825:107-118
pubmed: 29477657
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Drug Metab Rev. 2017 May;49(2):139-157
pubmed: 28290706
Front Pharmacol. 2020 Jun 19;11:932
pubmed: 32636751
Am J Gastroenterol. 2013 Dec;108(12):1861-8
pubmed: 24100261
Phytomedicine. 2019 Jan;52:272-283
pubmed: 30599908
Arch Virol. 2020 Sep;165(9):1935-1945
pubmed: 32594322
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276
pubmed: 29307986
J Biol Chem. 2007 Aug 24;282(34):24707-19
pubmed: 17575276
Hepatology. 2005 Jul;42(1):44-52
pubmed: 15895401
Eur J Pharmacol. 2011 Oct 15;668(3):467-71
pubmed: 21839075